Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. (ELTX): 6 pipeline candidates · ~4 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.1 months
D/E -16.79 · 0% dilution
Lead: Phase 2
6 candidates
N/A
N/A
A transparent, data-derived signal for Elicio Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$89.9M
Cash
$15.7M
Quarterly Burn
$11.6M
Runway
4.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| eli-002 | Phase 2 |
| eli-002 2p | Phase 1/Phase 2 |
| eli-002 7p | Phase 1/Phase 2 |
| eli-004 | Phase 1/Phase 2 |
| eli-007 | Phase 1/Phase 2 |
| eli-008 | Phase 1/Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
48
Total value held
$32.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,037,276 | $11.1M |
| susquehanna international group, llp | 373,804 | $4.0M |
| balyasny asset management l.p. | 244,814 | $2.6M |
| geode capital management, llc | 135,164 | $1.4M |
| renaissance technologies llc | 121,631 | $1.3M |
| jane street group, llc | 115,600 | $1.2M |
| millennium management llc | 92,762 | $992K |
| citadel advisors llc | 78,078 | $835K |
| marshall wace, llp | 74,512 | $797K |
| vanguard fiduciary trust co | 69,189 | $740K |
Showing top 10 of 48 institutional holders of Elicio Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Elicio Therapeutics, Inc.'s pipeline?
Elicio Therapeutics, Inc. (ELTX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Elicio Therapeutics, Inc.'s lead drug candidate?
Elicio Therapeutics, Inc.'s most advanced tracked candidate is eli-002 (Phase 2) for Minimal Residual Disease.
What is Elicio Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Elicio Therapeutics, Inc. has approximately 4.1 months of cash runway.
What is Elicio Therapeutics, Inc.'s market capitalization?
Elicio Therapeutics, Inc.'s market capitalization is approximately $89.9M.
Who is the CEO of Elicio Therapeutics, Inc.?
Mr. Robert T. Connelly is the chief executive officer of Elicio Therapeutics, Inc. (ELTX).
Get the full picture on Elicio Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.